Key Drivers
- Strong Cash Flow
- Margin Compression
- Elevated Leverage
AIAI Summary
Illumina's thesis has shifted to proving NovaSeq X placements can drive durable consumables-led growth and renewed operating leverage, but with shares already pricing in much of the recovery, investors should wait for sustained margin and free-cash-flow improvement before adding aggressively.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Margin Compression
- •Elevated Leverage
ILMN remains profitable with solid cash generation and manageable debt, but weakening margins/liquidity and sharply elevated valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong monthly rally
- •$245 resistance
- •Volatile pullback
ILMN gained about 12% over the last month, but with resistance near $245 and elevated volatility, watch $228–$229 support before chasing the rally.
Sharp one-session drop from $245.18 to $239.62 signals elevated volatility
Sentiment & News
Key News Insights:
- •Raised Guidance
- •S&P Inclusion
- •Margin Risks
Illumina's earnings beat, raised outlook, S&P 500 inclusion, and oncology growth strengthen momentum, though valuation and margin risks warrant caution.
Positive catalysts may support shares, but elevated valuation and cost pressures could limit upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings